trending Market Intelligence /marketintelligence/en/news-insights/trending/oGcEeDf2dcxW9Mp2SMATUw2 content esgSubNav
In This List

CytoDyn seeks to raise $3M from common stock offering

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery


CytoDyn seeks to raise $3M from common stock offering

CytoDyn Inc. is offering up to 4 million common shares to certain investors at a price of 75 cents per share.

The investors also received warrants to purchase up to 2 million shares, exercisable for five years from issuance at an exercise price of $1.00 per share.

Net proceeds to the company from the transactions, after deducting estimated offering expenses and excluding the proceeds from the exercise of the warrants, are expected to be about $3.0 million. CytoDyn will use the net proceeds from the offering to fund clinical trials of its products and for general corporate purposes.

The offering was expected to close Dec. 12., subject to customary closing conditions.